
Immunome Inc.
100
Recent developments highlight Immunome’s third quarter 2026 financial results, positive clinical updates, and increased analyst coverage reflecting interest in its oncology pipeline.
- Immunome reported third quarter 2026 financial results and provided a business update, including progress toward NDA submission for varegacestat and ongoing clinical trials for pipeline assets [N1].
- Multiple analysts initiated or maintained coverage with positive ratings, including William Blair initiating coverage at Outperform and HC Wainwright & Co. initiating coverage with a Buy recommendation [N3][N8].
- The company’s IM-1021 Phase 1 trial showed objective responses in B-cell lymphoma patients at multiple dose levels, with initial data presentations planned [N1].
- Immunome received FDA IND clearance for IM-1340 and planned a Phase 1 trial in solid tumors, expanding its ADC pipeline [N1].
- The company’s stock reached 52-week highs amid biotech sector strength, reflecting investor interest in Immunome’s clinical progress [N1].
Immunome Inc. is a clinical-stage biotechnology company specializing in the discovery, development, manufacturing, and commercialization of targeted oncology therapies, primarily antibody-drug conjugates (ADCs) and radioligand therapies (RLTs). The company’s pipeline includes three clinical-stage assets: varegacestat, an oral gamma secretase inhibitor for desmoid tumors; IM-1021, a ROR1-targeted ADC in Phase 1 trials for hematologic and solid tumors; and IM-3050, a FAP-targeted radioligand therapy candidate. Immunome also has three preclinical ADC candidates with planned IND submissions and ongoing discovery programs focused on novel targets and proprietary payloads. The company’s strategy emphasizes advancing clinical assets toward commercialization, leveraging ADC expertise, and pursuing selective business development opportunities to expand its pipeline and capabilities [S1].
Immunome Inc. is a biotechnology company focused on developing targeted oncology therapies, including antibody-drug conjugates and radioligand therapies. The company’s lead clinical asset, varegacestat, demonstrated positive Phase 3 results in desmoid tumors and is advancing toward an NDA submission. Additional pipeline assets include IM-1021 in Phase 1 trials for B-cell lymphomas and solid tumors, and IM-3050, a radioligand therapy candidate. As of September 30, 2026, Immunome reported $212.8 million in cash and equivalents, a strong liquidity position with a current ratio of 11.66, and a net loss of $85.8 million for the quarter. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
Immunome’s positive Phase 3 results for varegacestat in desmoid tumors indicate potential for regulatory approval and commercialization in a rare disease with significant unmet need. The company’s ADC platform, including IM-1021 with observed objective responses in B-cell lymphomas and solid tumors, and IM-3050 radioligand therapy, represent promising clinical-stage assets. The broad pipeline and discovery efforts targeting novel oncology markers could yield additional differentiated therapies. Strong liquidity supports ongoing development and operational activities. Multiple analyst initiations and positive coverage reflect market interest in Immunome’s clinical and strategic progress [N1][N3][N8].
Risks include the inherent uncertainties of clinical development and regulatory approval, particularly for novel therapies and indications. Varegacestat’s commercial success depends on regulatory outcomes and market adoption in a rare tumor segment. ADC and radioligand therapies face competitive pressures and potential safety or efficacy challenges. The company’s net losses and high operating expenses reflect ongoing investment needs, which may require additional financing. Execution risks include clinical trial outcomes, manufacturing scale-up, and commercialization capabilities. Market volatility and biotech sector dynamics may impact investor sentiment [S1][S2].
Immunome’s moat is based on its proprietary ADC technology platform, including a novel TOP1 inhibitor payload (HC74), and its focus on differentiated targets such as ROR1 and FAP that address unmet medical needs in oncology. The company’s clinical progress with varegacestat, demonstrating strong Phase 3 efficacy and safety data in a rare tumor indication, supports potential market differentiation. Its internal discovery capabilities and broad pipeline provide opportunities for sustained innovation. Additionally, leadership experience in developing and commercializing targeted cancer therapies contributes to execution capability [S1].
• Clinical and Regulatory Risk: Clinical trials may not confirm efficacy or safety, and regulatory approvals are uncertain, especially for novel oncology therapies.
• Commercialization Risk: Successful market adoption of varegacestat and other pipeline products depends on competitive landscape, payer acceptance, and physician uptake.
• Financial Risk: The company has reported net losses and relies on capital markets or partnerships to fund ongoing development and commercialization activities.
• Operational Risk: Execution challenges include manufacturing, supply chain, and scaling commercial infrastructure for new therapies.
Business trends: Advancement of targeted oncology therapies with a focus on ADCs and radioligand therapies, highlighted by positive Phase 3 results for varegacestat and ongoing clinical trials for IM-1021 and IM-3050.
Execution milestones: NDA submission for varegacestat, Phase 1 trial progress for IM-1021 and IM-1340, and continued pipeline expansion through IND submissions and discovery efforts.
Key risks: Clinical and regulatory uncertainties, commercialization challenges in competitive oncology markets, financial sustainability amid net losses, and operational execution risks.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, particularly antibody-drug conjugates (ADCs) and other oncology therapeutics [S1].
- The company’s pipeline includes three clinical assets and three preclinical assets, with a focus on oncology indications [S1].
- Varegacestat (formerly AL102) is an oral, once-daily gamma secretase inhibitor (GSI) in Phase 3 development for desmoid tumors, a rare, locally aggressive sarcoma [S1].
- In December 2025, Immunome reported positive topline Phase 3 RINGSIDE trial results for varegacestat, meeting all primary and key secondary endpoints, including an 84% reduction in risk of disease progression or death versus placebo and a 56% objective response rate versus 9% for placebo [S1].
- The company planned an NDA submission for varegacestat in the second quarter of 2026 [S1].
- IM-1021 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) ADC incorporating a proprietary TOP1 inhibitor payload, in Phase 1 trials for B-cell lymphomas and solid tumors, with observed objective responses at multiple dose levels [S1].
- IM-3050 is a fibroblast activation protein (FAP)-targeted lutetium-177 radioligand therapy (RLT) candidate for solid tumors, designed to deliver targeted radiation to tumor stromal cells [S1].
- The company has additional preclinical ADC assets (IM-1617, IM-1340, IM-1335) with anticipated IND submissions in 2026 and ongoing discovery efforts for novel ADCs [S1].
- Immunome reported cash and cash equivalents of $212.8 million as of September 30, 2026, with current assets of $477.8 million and current liabilities of $40.97 million, resulting in a strong current ratio of 11.66 and a cash ratio of 5.2 [S2].
- For the three months ended September 30, 2026, Immunome reported a net loss of $85.8 million and basic and diluted EPS of -$0.76 [S2].
- The company’s strategy includes advancing varegacestat toward potential commercialization, leveraging ADC capabilities to progress pipeline assets, and pursuing selective business development opportunities [S1].
- Recent news includes the third quarter 2026 financial results and business update, ongoing clinical data presentations, and multiple analyst coverage initiations and recommendations [N1][N3][N8].
Generated 2026-11-10
- S1 | 2026-03-03 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Immunome, Inc. Reports Third Quarter 2026 Financial Results and Provides Business Update | https://www.nasdaq.com/articles/immunome-inc-reports-third-quarter-2026-financial-results-and-provides-business-update
- N2 | 2026-11-04 | www.nasdaq.com | 4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates | https://www.nasdaq.com/articles/4-biotech-stocks-likely-outpace-q3-earnings-estimates
- N3 | 2026-10-17 | www.nasdaq.com | William Blair Initiates Coverage of Immunome at Outperform | https://www.nasdaq.com/articles/william-blair-initiates-coverage-immunome-outperform
- N4 | 2026-06-05 | www.nasdaq.com | 4 Biotech Stocks Investors Should Watch in 2026 | https://www.nasdaq.com/articles/4-biotech-stocks-investors-should-watch-2026
- N5 | 2026-05-06 | www.nasdaq.com | Techne (TECH) Misses Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/techne-tech-misses-q3-earnings-and-revenue-estimates
- N6 | 2026-05-05 | www.nasdaq.com | Exelixis (EXEL) Tops Q1 Earnings Estimates | https://www.nasdaq.com/articles/exelixis-exel-tops-q1-earnings-estimates
- N7 | 2026-05-04 | www.nasdaq.com | CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/crispr-therapeutics-ag-crsp-reports-q1-loss-lags-revenue-estimates
- N8 | 2026-02-12 | www.nasdaq.com | HC Wainwright & Co. Initiates Coverage of Immunome (IMNM) with Buy Recommendation | https://www.nasdaq.com/articles/hc-wainwright-co-initiates-coverage-immunome-imnm-buy-recommendation
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


